The patient incidence of adverse events in the safety analysis set ( all patients who received at least one dose of study drug ) did not differ between the denosumab group ( @ events , @ % ) and the placebo group ( @ events , @ % ) , nor did the numbers of serious adverse events ( @ vs @ -LSB- @ % in each group -RSB- ) .